SAN DIEGO, Calif.--(BUSINESS WIRE)--Biological Dynamics, a molecular diagnostics company dedicated to improving global health outcomes by empowering global communities with low-cost, accessible cancer diagnostics, today announced that new data on the company’s novel technology (ACE) will be presented at the American Association for Cancer Research 2018 Annual Meeting, at McCormick Place Convention Center on April 13 – 18 in Chicago.
Abstracts from two studies examining the application of the company’s technology as an isolation platform for a novel class of biomarkers, such as extracellular vesicles (EVs), and as a cell-free DNA (cfDNA)-based diagnostic assay, will be presented:
AC Electrokinetic Platform for Rapid Isolation and Characterization of
Extracellular Vesicles from NSCLC Patients
Presented by Raj Krishnan, Ph.D., CEO of Biological Dynamics, on April 16 at 1:00 p.m. CT in Section 44. (Late-breaking abstract # LB-174)
Application of Novel ACE Technology: Treatment Response Monitoring via
Quantification of Cell-Free DNA (cfDNA) in Plasma from Late-Stage
Presented by Robert Kovelman, Ph.D., Biological Dynamics’ Sr. Director of Assay Development and Clinical Affairs, on April 17 at 8:00 a.m. CT in Section 27. (Abstract # 3666)
Biological Dynamics announced on Friday, April 13, the addition of two new members to its Board of Directors. Irwin Jacobs, founding Chairman and CEO Emeritus of Qualcomm and Chairman Emeritus of the Salk Institute for Biological Studies, and Martin J. Wygod, founder of Medco Containment Services Inc. and former Chairman of WebMD Health Corp., have joined Biological Dynamics’ Board of Directors. (Read more here.)
About Biological Dynamics
Biological Dynamics is an innovative diagnostic company committed to improving global cancer outcomes by empowering healthcare communities with low-cost, accessible cancer diagnostics for labs and homes. The company’s lab-on-a-chip platform offers a novel way to isolate cell-free nanoparticles and macromolecules directly from whole blood, serum, or plasma. The company is developing a suite of novel oncology tests for early cancer detection, treatment response, and recurrence monitoring. In addition to lab-focused products, the company is also developing a smartphone-enabled portable version of the platform, extending molecular testing into homes. For more information visit us at www.biologicaldynamics.com and follow us at @BiodynSD on Twitter.